ETOPOSIDE
Bladder Small Cell Neuroendocrine Carcinoma
Jonsson Comprehensive Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Bladder Small Cell Neuroendocrine Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | B |
Lurbinectedin National Cancer Institute (NCI) | Phase 2 | CCC |
[212pb]pb-mp0712 Molecular Partners AG | Phase 1/2 | CCC |
View all 11 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →